Management of drug toxicities in chronic myeloid leukaemia.
about
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Hematologic toxicities of small molecule tyrosine kinase inhibitors.Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study.Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailyCritical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.The treatment of pediatric chronic myelogenous leukemia in the imatinib eraManaging chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy.Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents.Role of allo-SCT for CML in 2010.Development of an effective therapy for chronic myelogenous leukemiaCharacteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications.Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.Dasatinib Induced Cardiac Tamponade-A Rare Association.Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment.Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.
P2860
Q30891587-6D2FD8EE-A5E9-428F-A0A5-8A8B9AE2F987Q33398485-EAF96E2F-37CA-4A0B-9CD9-EC34584AEA12Q33420661-C0EE8249-E6BD-45F6-8DD5-FC7A6D5DFA1FQ34451624-675241BD-AA4A-48C2-98BA-7DE5076147F8Q34894883-4C0972D1-C2B6-4BF1-8072-B07CD58F7152Q35062049-B7226DF6-5099-48CA-B58A-61B8EDFE7B80Q36355098-E7293566-89B3-4CD6-B12C-8350004AFFC7Q36392642-ADC1571E-782E-4C39-97BE-04AFBA80D1A4Q37630453-E322CFE0-4D24-4DC1-B7AF-2FFCC95BE952Q37763106-77D11491-90AC-4531-9307-8264E289AE29Q37763493-79E492B7-BA45-4D4A-9C8C-18F65AEFC80BQ37966917-82CFFCC4-A86A-4C53-83CA-D52ABF0A005DQ37977471-D47B6FE2-B43C-4567-B1CA-D195EC9BFD22Q38148243-6EA2BBB4-7A40-4D72-A0B9-48865A4A4DD6Q42293055-B3059D45-8D22-4C8E-A05C-F57C3CE4C53AQ44383576-75A10E15-1DAD-404A-AA1B-F9818339923BQ47135575-18586833-62DB-4D3C-A3A9-ABE96C1F42E8Q51072279-782BC0AA-B7F8-46D7-832B-EC4969F128FC
P2860
Management of drug toxicities in chronic myeloid leukaemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of drug toxicities in chronic myeloid leukaemia.
@en
Management of drug toxicities in chronic myeloid leukaemia.
@nl
type
label
Management of drug toxicities in chronic myeloid leukaemia.
@en
Management of drug toxicities in chronic myeloid leukaemia.
@nl
prefLabel
Management of drug toxicities in chronic myeloid leukaemia.
@en
Management of drug toxicities in chronic myeloid leukaemia.
@nl
P1476
Management of drug toxicities in chronic myeloid leukaemia.
@en
P2093
Michael J Mauro
Michael W Deininger
P304
P356
10.1016/J.BEHA.2009.06.001
P577
2009-09-01T00:00:00Z